Abstract Chronic graft versus host disease (cGVHD) is a common late complication of allogenic hematopoietic stem cell transplant (HSCT). We analyzed risk factors, pattern and long term transplant outcomes of cGVHD at a tertiary cancer centre. Seventy-seven consecutive patients who underwent HSCT for acute leukemia were included. Forty (52 %) patients developed cGVHD; 24 (60 %) extensive stage while 16 (40 %) limited stage. Oral cavity was the commonest site of involvement (25 patients) followed by liver, skin and lung. We found that female donor to male recipient transplant and diagnosis of acute lymphoblastic leukemia (ALL) were the only factors associated with increased risk of cGVHD. The incidence of leukemia relapse was 18 % in patients who developed cGVHD compared to 51 % in those who did not (P = 0.002). Four year overall survival and relapse free survival (RFS) were 62 and 46 % in patients who developed cGVHD compared to 29 % (P \ 0.001) and 29 % (P \ 0.001) in patients who did not develop cGVHD, respectively. We conclude that cGVHD is more common in male patients with female donors and in patients transplanted for ALL. Oral cavity is the commonest site of cGVHD in our patients and transplant related survival outcomes are superior in patients who develop cGVHD.
Introduction
Chronic graft versus host disease (cGVHD) is a late complication of allogenic hematopoietic stem cell transplantation (HSCT) and is a major cause of morbidity and mortality [1] . The incidence of cGVHD has varied from 30 to 70 % across studies [2, 3] . However, these studies are quite heterogeneous with respect to factors like diagnoses, patient-donor characteristics, type of conditioning regimen, stem cell source and GVHD prophylaxis used [2, 4, 5] . Development of cGVHD is associated with improvement in relapse free survival [2, 5, 6] . However, the impact on overall survival is less clear [2, 5] . There is limited data regarding risk factors and transplant related outcomes of cGVHD in patients with acute leukemia. In this study, we sought to determine the incidence, pattern and the risk factors for cGVHD in acute leukemia patients undergoing HSCT. We also aimed to assess the impact of cGVHD on transplant related outcomes including incidence of leukemia relapse, incidence of infective complications, relapse free survival (RFS) and overall survival (OS).
Patients and Methods

Patient and Transplant Characteristics
All patients who underwent allogeneic HSCT for acute leukemia from January 2008 to March 2013 were included in this retrospective study. Relevant data was collected from patient case records and electronic medical records. Acute myeloid leukemia (AML) patients were transplanted either in remission (Complete remission [CR]-1 or CR-2) or in disease. However, patients with ALL were transplanted only in complete remission. Poor risk acute myeloid leukemia (AML) was characterized by at least one of the following: unfavorable cytogenetics [complex karyotype, monosomal karyotype, del 5, del 7, 5q-, 7q-, inv(3), t(3;3), t(6;9), 11q23 translocations], total leukocyte count (TLC) [100 9 10 9 /L at baseline, not achieving CR after induction, disease stage C CR-2 or persistent disease at transplant. High risk acute lymphoblastic leukemia (ALL) was defined by at least one of the following characteristicspoor risk cytogenetics [t(9;22), t(1;19), t(4;11), hypodiploidy, complex karyotype], TLC[100 9 10 9 /L at baseline, not achieving CR after induction, disease stage C CR-2 or persistent disease at transplant. Human leucocyte antigen (HLA) typing for all patients and donors was done by polymerase chain reaction with sequence specific primers (SSP). Matching was done at HLA-A, HLA-B and HLA-DRB1 for all patient and donor pairs. Those with less than full match or those with unrelated donors underwent additional testing for HLA-C and HLA-DQB1. Depending on donor availability and HLA matching, patients underwent either matched related donor (MRD) transplant or matched unrelated donor (MUD) transplant or haploidentical donor (HID) transplant. All patients received conditioning chemotherapy with either full intensity regimens (busulfan-cyclophosphamide or total body irradiation-cyclophosphamide) or with reduced intensity regimens (Fludarabine based). Reduced intensity regimens were used in those patients who had significant comorbidities or those with borderline performance status. Rabbit anti thymocyte globulin (ATG) was used in matched unrelated donor transplants and in those with one antigen mismatched related donor transplants. Stem cell graft was either T cell replete peripheral blood stem cells (PBSCs) or bone marrow harvest or cord blood derived stem cells.
GVHD Prophylaxis and Treatment
GVHD prophylaxis consisted of either cyclosporine (CsA) with methotrexate (MTX) or CsA with mycophenolate mofetil (MMF). MMF was used in patients who participated in an ongoing MMF pharmacokinetic study [7] . CsA was given at a starting dose of 1.5 mg/kg twice daily intravenously (iv) from day-1. MTX was given iv at 15 mg/m 2 on D1 and 10 mg/m 2 on D3, D6 and D11. Leucovorin rescue was given 24 h after methotrexate. MMF was given at a dose of 600 mg/m 2 twice a day from day-1 to day ?30. GVHD prophylaxis in patients undergoing haplo-identical transplant consisted of CsA?MMF (started on day ?5 with MMF dose being 15 mg/kg thrice daily till day ?35) along with post transplant cyclophosphamide (50 mg/kg on day ?3 and day ?4). CsA was tapered by 10 % per week from day ?90. However, in patients with high risk of relapse, CsA tapering was started early at day ?45 to ?60. Diagnosis of cGVHD was made clinically and defined as extensive stage disease or limited stage disease according to standard criteria [8] . Topical steroids were used for treatment of limited stage cGVHD involving skin, oral cavity and upper gut. Systemic steroids were used in patients with visceral GVHD and in those who did not respond to topical steroids. Additionally, for lung GVHD, we used azithromycin for its immune modulatory properties, imatinib as anti-fibrosis agent and montelukast as mast cell stabilizer. CsA or MMF were used as steroid sparing agents or as second line drugs in patients whose GVHD was steroid refractory or when the disease flared up as steroids were being tapered.
Anti-infective Prophylaxis
All patients received acyclovir 400 mg thrice daily for 6 months, levofloxacin 500 mg once daily or ciprofloxacin 500 mg twice daily for 3 months, cotrimoxazole (160 mg/ 800 mg) twice daily on Saturdays and Sundays for 1 year and IVIG 200 mg/kg on day ?1, ?21, ?42, ?63, ?84. These prophylactic medications were started along with the start of conditioning regimen. Voriconazole or posaconazole was used as antifungal prophylaxis for 3 months post transplant. Patients who developed acute or chronic GVHD and were on steroids continued with acyclovir, fluoroquinolone, cotrimoxazole and antifungal prophylaxis till they remained on steroids beyond the above time periods.
Statistical Analysis
Patients were divided in 2 groups depending on development of cGVHD. Group A included those who developed cGVHD (both limited and extensive stage) while group B included those who did not develop cGVHD. In this analysis, we also included patients not surviving till day ?100 post HSCT since chronic GVHD is known to occur prior to day ?100 [9] . We analyzed patient and donor age, diagnosis, gender mismatch, disease status at transplant, stem cell source, use of ATG, GVHD prophylaxis, degree of HLA match, CD3 and CD34 cells infused and acute GVHD as potential risk factors for cGVHD. Incidence of relapse, slippage of chimerism, RFS and OS were evaluated as outcome measures. Development of viral and fungal infections was also analyzed. Categorical data was analyzed using Chi square test and continuous data with Mann-Whitney test. Multivariate analysis was done using logistic regression analysis. All P values were 2 sided. Survival analysis was done with Kaplan-Meier method. SPSS version 18 was used for statistical analyses.
Results
Patient and Transplant Characteristics
Seventy seven patients underwent HSCT for acute leukemia during the study period. The baseline patient and transplant characteristics are summarized in Table 1 . The median follow up time for the entire cohort of patients was 26 months.
Incidence and Pattern of Chronic GVHD Forty (52 %) developed chronic GVHD; 60 % of these were extensive stage ( Table 2 ). The median time to the onset of chronic GVHD was 150 days (range 35-456 days). Chronic GVHD was de novo in 19 patients. Thrombocytopenia at onset was present in six patients. Oral cavity was the commonest site involved (25 patients) followed by liver, skin and lung (Fig. 1) . Twenty three patients (58 %) required systemic steroids and median duration of use of systemic steroids was 116 days.
Risk Factors for Chronic GVHD
Several patient, donor and transplant related factors were evaluated as potential risk factors for chronic GVHD (Table 3) . Three factors were found to be significantly associated with increased risk of cGVHD on univariate analysis-diagnosis of ALL, female donor to male recipient transplants and lower CD3 cell dose infused. On multivariate analysis, female donor to male recipient transplant (P = 0.015) and diagnosis of ALL (P = 0.05) were the only factors associated with increased risk of cGVHD (Table 4) .
Transplant Related Outcomes
There was no difference in the median time to neutrophil and platelet engraftment between the 2 groups (P = NS). Incidence of relapse was 18 % among patients with cGVHD and 51 % among patients without cGVHD (p = 0.002). Similarly incidence of slippage of chimerism was also significant lower in patients who developed cGVHD (p = 0.006). Transplant related mortality was similar in both the groups (P = 0.63). Median OS, 4 year OS, median RFS and 4 year RFS were all significantly greater (P \ 0.001) in patients who developed cGVHD compared to those who did not (Table 5, Figs. 2, 3 ). Among patients with chronic GVHD, the 4 year RFS was similar for patients of AML vs ALL (39 vs 84 %, p = 0.45). Similarly, no significant difference was found in overall survival according to diagnosis of AML versus ALL (4 year OS 45 vs 84 %, p = 0.19). Similar findings were seen among patients without chronic GVHD. Haplo-identical transplant 5 7
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Infective Complications
The incidence of cytomegalovirus (CMV), Epstein Barr Virus, adenovirus and BK virus reactivation were similar in both groups. The median number of episodes of CMV reactivation was also similar. Additionally, incidence of fungal infections was also similar in patients with or without GVHD (Table 6 ).
Discussion
Allogenic HSCT has resulted in long term cure of a significant fraction of patients with acute leukemia including relapsed and refractory cases. Chronic GVHD remain a significant cause of morbidity in the post-transplant period. It usually has onset after 100 days, but can manifest even earlier [9] . Overlap GVHD syndromes with features of both acute and chronic GVHD have been described. Hence, clinical manifestations rather than the time of onset are considered more important in classifying GVHD [9] . In the last 2 decades, few studies have looked into the risk factors, transplant outcomes and infective complications in patients with chronic GVHD. Various studies have shown that older patient age, female donor to male recipient transplant, mismatched or unrelated donor, PBSCs as the source of stem cells and development of acute GVHD are associated with the development of chronic GVHD. Few studies also found that CMV reactivation, higher infused CD34 cell dose and lack of MTX in GVHD prophylaxis are also risk factors for cGVHD [10] . In our study, we found a strong correlation between female donor to male recipient transplant and the development of cGVHD. Lesser number of unrelated donor transplants and mismatched transplants in our study probably explain why these risk factors did not turn out significant. Similarly, more than 90 % patients had PBSCs as the source of stem cell graft; this could explain the lack of effect of source of stem cells on the development of cGVHD. In contrast to what has been reported earlier [2] , we did not find a correlation between prior acute GVHD and increased risk for cGVHD. This could be due to the fact that a higher proportion of patients (65 %) in our study received reduced intensity conditioning regimen. Studies have shown that in patients undergoing reduced intensity transplantation, acute GVHD may not predict for the development of cGVHD [5] . Additionally, we found diagnosis of ALL to be associated with the development of chronic GVHD. The exact reason behind this remains unclear. Infused CD3 cell count was significant on univariate analysis. Analysis of infused CD3 count as risk factor for chronic GVHD has yielded variable results between studies [11, 12] .
The pattern of organ involvement in cGVHD seen in our study is similar to that reported previously with oral cavity, liver, skin and lung being the commonly involved sites [13] . Nearly half of patients with cGVHD had de novo cGVHD which is similar to the proportion reported previously in other studies [5, 13, 14] . Regarding transplant outcomes, it is relatively clear that cGVHD improves disease free survival [2, 5, 6] and our study also concurs with previous studies. The impact on overall survival is less consistent [2, 5] . Only few studies have shown a correlation between extensive stage cGVHD and overall survival [14] . In our study, we found a strong positive correlation between occurrence of cGVHD and improvement in OS. This improvement was noted in the entire cohort of patients with cGVHD irrespective of the severity of GVHD. The improvement is OS seen in patients who developed cGVHD is attributed to decrease in the incidence of leukemia relapse. This favorable impact of cGVHD on transplant outcome is related to increased graft versus leukemia effect in these patients. The improvement in OS might also be related to the fact that there was no increase in the incidence of infective complications in patients who developed cGVHD compared to those who did not. While previous studies have shown that infective complications are a major cause of mortality in patients with cGVHD (particularly fungal infections) [15] , we found no increase in the incidence of infective complications in our cohort of patients with cGVHD. We conclude that cGVHD complicates nearly half of all acute leukemia transplants. Female donor to male recipient and diagnosis of ALL are important risk factors for the development of cGVHD. Occurrence of cGVHD is associated with decrease in leukemia relapse and an improvement in overall survival.
Conflict of interest
The authors declare no conflict of interest. 
